Sequential chemotherapy for advanced colorectal cancer: Should we ever start with a single cytotoxic agent?

Current Colorectal Cancer Reports

Volumn 4, Issue 3, 2008, Pages 130-138

  Seymour, Matthew T ^a   Punt, Cornelis J A ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053293349     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-008-0022-1     Document Type: Article

References (27)

1. De Gramont A, Figer A, Seymour MT, et al.: A randomized trial of leucovorin and 5-f uorouracil with or without oxaliplatin in advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1998, 17: 985.
2. Giacchetti S, Zidani R, Perpoint B, et al.: Phase III trial of 5-f uorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) [abstract 805]. Proc Am Soc Clin Oncol 1997, 16: 229a.
3. Douillard JY, Cunningham D, Roth AD, et al.: A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT) [abstract 899]. Proc Am Soc Clin Oncol 1999, 18: 233a.
4. Saltz LB, Locker PK, Pirotta N, et al.: Weeklyir inotec an (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily × 5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC) [abstract 898]. Proc Am Soc Clin Oncol 1999, 18: 233a.
5. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chrono-modulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18: 136-147.
6. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938-2947.
7. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355: 1041-1047. Erratum in Lancet 2000, 355: 1372.
8. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343: 905-914.
9. Grothey A, Deschler B, Kroening H, et al.: Phase III study of bolus 5-f uorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC) [abstract 512]. Proc Am Soc Clin Oncol 2002, 21: 129a.
10. Köhne CH, van Cutsem E, Wils J, et al.: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005, 23: 4856-4865.
11. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22: 23-30.
12. Punt CJ: New options and old dilemmas in the treatment of patients with advanced colorectal cancer [review]. Ann Oncol 2004, 15: 1453-1459.
13. National Institute for Clinical Excellence (NICE): Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Technology Appraisal Guidance no. London: National Institute for Clinical Excellence (NICE); 2002.
14. Seymour MT, Maughan TS, Ledermann JA, et al.: Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370: 143-152.
15. Seymour MT, Maughan TS, Wasan HS, et al.: Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial [abstract 9030]. J Clin Oncol 2007, 25 (2007 ASCO Annual Meeting Proceedings Part I).
16. Koopman M, Antonini NF, Douma J, et al.: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370: 135-142.
17. Bouché O, Castaing M, Etienne PL, et al.: Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results [abstract 4069]. J Clin Oncol 2007, 25 (2007 ASCO Annual Meeting Proceedings Part I).
18. Pluzanska A, Mainwaring P, Cassidy J, et al.: Final results of a randomized phase III study evaluating the addition of oxaliplatin first line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (LIFE study) [abstract 3517]. J Clin Oncol 2005, 23 (2005 ASCO Annual Meeting Proceedings Part I).
19. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21: 2059-2069.
20. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22: 229-237.
21. Grothey A, Sargent D: Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23: 9441-9442.
22. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
23. Folprecht G, Grothey A, Albert S, et al.: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16: 1311-1319.
24. Benoist S, Brouquet A, Penna C, et al.: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006, 24: 3939-3945.
25. Braun MS, Richman SD, Quirke P, et al.: Predictive biomarkers of chemotherapy eff cacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26: 2690-2698.
26. Schmoll HJ, Sargent D: Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? [comment]. Lancet 2007, 370: 105-107.
27. Seymour MT, Punt CJ: CAIRO and FOCUS [letter]. Lancet 2007, 370: 1904-1905, author reply 1905.